Prolight Diagnostics publishes quarterly report Q1, 2023
Financial overviewFirst quarter Q1 2023 Group(figures in brackets only refer to March 2022 as the group was formed on 1 March 2022) Net sales amounted to 0. Other operating income amounted toKSEK 39 (1,298). The profit after tax amounted to kSEK –7,580 (-3,675) Earnings per share before and after dilution: SEK-0.03 (-0.02). Cash flow from […]
Annual General Meeting of Prolight Diagnostics AB (publ) on 11 May 2023
The Annual General Meeting (AGM) of Prolight Diagnostics AB (publ) took place on 11 May 2023 in Lund. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdiagnostics.se. The AGM resolved in accordance with all of the motions presented in the notification of the AGM. Resolution regarding the adoption of […]
Prolight Diagnostics submits patent applications for multiplex testing and enhancing dynamic range
Prolight Diagnostics (“Prolight”) today announces that the company’s subsidiary Psyros Diagnostics (“Psyros”) has submitted two priority patent applications covering various aspects of multiplexing capabilities to the Intellectual Property Office in Great Britain. The first application covers various aspects of multiplexing (i.e., detecting several different biomarkers at the same time on a single sample). By using […]
Annual report for 2022
Prolight Diagnostics AB (publ) announces that the annual report for 2022 is now available on the company’s website, https://prolightdiagnostics.se/en/investor-relations/financial-reports/ and in the attached appendix. For further information, please contact:Prolight Diagnostics AB (publ)E-mail: ub@prolightdiagnostics.seTelephone: +46 73 582 39 87Website: www.prolightdiagnostics.se/en/ About UsProlight Diagnostics, together with the subsidiary Psyros Diagnostics and technology partners, develops innovative and flexible […]
NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), corp. Reg. no. 556570-9499, (the ”Company”) are hereby notified of the Annual General Meeting to be held on Thursday 11 May 2023 at 2 p.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification of attendanceShareholders who wish to participate in the Annual General Meeting must:– […]
Prolight Diagnostics publishes year-end report 2022
Financial overviewFourth quarter Q4 2022 GroupFormed March 1, 2022 Other operating income amounted to kSEK 2,050. The profit after tax amounted to kSEK -2,809. Earnings per share before and after dilution: SEK -0.01. Cash flow from current operations was kSEK -5,436. Cash and cash equivalents amounted to kSEK 54,111 as of December 31, 2022. Fourth […]
Prolight Diagnostics selects ITL (a G&H Company) to develop commercial instrument
Prolight Diagnostics (“Prolight”) today announces that it has selected Integrated Technologies Limited (“ITL”) to develop the commercial instrument for its point-of-care digital immunoassay system. This next stage of product development builds on the prototypes developed in-house at Prolight’s subsidiary Psyros Diagnostics (“Psyros”) and will ensure that the commercial instrument is state of the art and […]
Prolight Diagnostics Delivers on SBRI Healthcare Grant
Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has successfully completed the SBRI Healthcare phase 2 award, accelerating development of its unique digital immunoassay. Psyros received the SBRI Healthcare phase 2 grant of approximately 1 million GBP last year, requiring the completion of certain milestones. Psyros has now met or exceeded all […]
Prolight Diagnostics shows proof-of-performance for high-sensitive immuno assay
Prolight Diagnostics (“Prolight”) today announced that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance that its high-sensitivity immunoassay is capable of reproducibly detecting low levels of specific proteins in a digital manner. “This is a very important step on our journey to develop a high-sensitivity assay for digitally detecting troponin. Such an […]
Prolight Diagnostics signs commercialisation agreement for PLD Micro Flex
Prolight Diagnostics AB today announces that it has signed a commercialisation agreement for its proprietary point-of-care (POC) platform PLD Micro Flex with its technology and development partner, The Technology Partnership plc (TTP), in Cambridge, UK. Under the agreement, TTP will pursue further development and ongoing external initiatives and discussions with the aim of securing an […]
